Fechter Pierre, Cruz Da Silva Elisabete, Mercier Marie-Cécile, Noulet Fanny, Etienne-Seloum Nelly, Guenot Dominique, Lehmann Maxime, Vauchelles Romain, Martin Sophie, Lelong-Rebel Isabelle, Ray Anne-Marie, Seguin Cendrine, Dontenwill Monique, Choulier Laurence
CNRS, UMR 7242, Biotechnologie et Signalisation Cellulaire, Institut de Recherche de l'Ecole de Biotechnologie de Strasbourg, Université de Strasbourg, 67400 Illkirch-Graffenstaden, France.
CNRS, UMR 7021, Laboratoire de Bioimagerie et Pathologies, Tumoral Signaling and Therapeutic Targets, Faculté de Pharmacie, Université de Strasbourg, 67401 Illkirch, France.
Mol Ther Nucleic Acids. 2019 Sep 6;17:63-77. doi: 10.1016/j.omtn.2019.05.006. Epub 2019 May 24.
Nucleic acid aptamers are often referred to as chemical antibodies. Because they possess several advantages, like their smaller size, temperature stability, ease of chemical modification, lack of immunogenicity and toxicity, and lower cost of production, aptamers are promising tools for clinical applications. Aptamers against cell surface protein biomarkers are of particular interest for cancer diagnosis and targeted therapy. In this study, we identified and characterized RNA aptamers targeting cells expressing integrin α5β1. This αβ heterodimeric cell surface receptor is implicated in tumor angiogenesis and solid tumor aggressiveness. In glioblastoma, integrin α5β1 expression is associated with an aggressive phenotype and a decrease in patient survival. We used a complex and original hybrid SELEX (selective evolution of ligands by exponential enrichment) strategy combining protein-SELEX cycles on the recombinant α5β1 protein, surrounded by cell-SELEX cycles using two different cell lines. We identified aptamer H02, able to differentiate, in cyto- and histofluorescence assays, glioblastoma cell lines, and tissues from patient-derived tumor xenografts according to their α5 expression levels. Aptamer H02 is therefore an interesting tool for glioblastoma tumor characterization.
核酸适配体通常被称为化学抗体。由于它们具有多种优势,如尺寸更小、温度稳定性好、易于化学修饰、缺乏免疫原性和毒性以及生产成本较低,适配体是临床应用中很有前景的工具。针对细胞表面蛋白生物标志物的适配体在癌症诊断和靶向治疗方面特别受关注。在本研究中,我们鉴定并表征了靶向表达整合素α5β1的细胞的RNA适配体。这种αβ异二聚体细胞表面受体与肿瘤血管生成和实体瘤侵袭性有关。在胶质母细胞瘤中,整合素α5β1的表达与侵袭性表型和患者生存率降低相关。我们使用了一种复杂且独特的杂交SELEX(指数富集配体的系统进化)策略,该策略结合了在重组α5β1蛋白上进行的蛋白质SELEX循环以及使用两种不同细胞系进行的细胞SELEX循环。我们鉴定出了适配体H02,在细胞和组织荧光测定中,它能够根据胶质母细胞瘤细胞系以及患者来源的肿瘤异种移植组织的α5表达水平进行区分。因此,适配体H02是胶质母细胞瘤肿瘤表征的一个有趣工具。